Entrepreneur Briefs

No Conclusion Yet On Value Of Imreg-1 It was lmreg Inc., of New Orleans, La., playing David opposite the well-established, well-heeled, well-staffed, pharmaceutical Goliaths last summer. At that time, lmreg was one of the five companies in the race to develop anti-AIDS drugs that had completed FDA clinical trials for its AIDS products—and with nine scientists on board it was by far the smallest firm. (See “A Tiny Biotech Startup Wages War Against AIDS,” The Scientist, August


Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

It was lmreg Inc., of New Orleans, La., playing David opposite the well-established, well-heeled, well-staffed, pharmaceutical Goliaths last summer. At that time, lmreg was one of the five companies in the race to develop anti-AIDS drugs that had completed FDA clinical trials for its AIDS products—and with nine scientists on board it was by far the smallest firm. (See “A Tiny Biotech Startup Wages War Against AIDS,” The Scientist, August 8, 1988, page 1.) It was a promising start for the company, which was founded by a husband and wife who are both Tulane University professors: But lately all hasn’t been smooth sailing for the drug startup. An FDA meeting on April 7 yielded inconclusive results for Imreg-1,the drug the company hopes to market for patients with AIDS-related complex. After an all-day session, the FDA staff concluded that Imreg-1 was no better than a placebo, an assessment that Imreg rebutted. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide